Tesamorelin before and after: when are results visible?

Tesamorelin usually begins to cause a measurable reduction in visceral abdominal fat within about 3 to 6 months of daily use. More noticeable improvements in body composition, liver fat levels, and metabolic health are often observed after 6 to 12 months of continued therapy [1–7]. Clinical trials demonstrating the effects of Tesamorelin before and after consistently show a gradual reduction in deep abdominal fat, a decrease in waist circumference, improved liver fat levels, and support in maintaining lean body mass.

Early „before and after” changes during tesamorelin treatment are often reported within the first 12 to 26 weeks of treatment. In a randomized, placebo-controlled trial conducted by Falutz J et al. (2007), HIV-positive individuals taking 2 mg of tesamorelin daily achieved an approximately 15% reduction in visceral abdominal fat after 26 weeks compared to placebo [1]. Participants also showed improvements in waist circumference, triglyceride levels, and cholesterol profiles during the same treatment period.

Similar results were reported by Falutz J et al. (2010), who analyzed two large Phase III clinical trials involving 806 HIV-positive individuals with excessive abdominal fat [2]. After 26 weeks, tesamorelin reduced visceral fat by approximately 15.4%. The researchers also observed significant improvements in waist circumference and body image-related concerns during this period. Participants who continued treatment maintained or further improved these reductions for 52 weeks, whereas those who discontinued therapy gradually regained abdominal fat over time.

The time required to reduce liver fat may be slightly longer than the time required to see noticeable changes in abdominal fat. In a randomized clinical trial conducted by Stanley TL et al. (2014), participants treated with tesamorelin for 6 months experienced a significant reduction in both visceral abdominal fat and liver fat compared to placebo [3]. Long-term results by Stanley TL et al. (2019) showed that after 12 months of treatment, tesamorelin reduced liver fat by approximately 37% from baseline in individuals with HIV-associated non-alcoholic fatty liver disease (NAFLD) [4]. Hepatic fat refers to fat stored within the liver. After one year, 35% of participants receiving tesamorelin achieved a hepatic fat level below 5%, compared to only 4% in the placebo group.

Research also suggests that tesamorelin may improve muscle quality and overall body composition during the same treatment period. Adrian S et al. (2019) found that participants responding to tesamorelin after 26 weeks experienced improvements in muscle density and muscle area while simultaneously decreasing visceral fat [5]. Muscle density refers to muscle quality and composition, suggesting that „before and after” changes may include both a reduction in abdominal fat and preservation or improvement of lean tissue.

The speed and scope of tesamorelin's effects can vary depending on the baseline metabolic state, treatment regularity, and individual physiology. According to Mangili A et al. (2015), individuals with metabolic syndrome, elevated triglyceride levels, obesity, and higher cardiovascular risk markers often achieved greater reductions in visceral fat during tesamorelin therapy [6].

Importantly, studies consistently show that continued treatment may be necessary to maintain the fat-reduction effects achieved with tesamorelin. In a long-term study by Falutz J et al. (2008), participants who discontinued tesamorelin after initial improvement relatively quickly regained abdominal fat, while those who continued therapy maintained approximately 18% of visceral fat reduction for 52 weeks [7]. These results suggest that the metabolic effects of tesamorelin depend on continuous stimulation of the body’s natural growth hormone pathway.

Generally speaking, current clinical evidence suggests that tesamorelin may begin to cause visible and measurable reductions in abdominal fat within about 3 to 6 months, while greater improvements in liver fat, metabolic health, and body composition often continue to develop over 6 to 12 months of consistent daily treatment [1–7].

Disclaimer

The content is for educational and informational purposes only. It should not be interpreted as medical advice, diagnosis, or therapeutic recommendations. Tesamorelin is a prescription medication primarily approved for the treatment of HIV-related lipodystrophy. Individual responses to treatment may vary, and therapies affecting growth hormone pathways require medical supervision, laboratory monitoring, and individual clinical assessment by a qualified healthcare professional.

References

1. Falutz J, Allas, S., Blot, K., et al. (2007). Metabolic effects of a growth hormone-releasing factor in patients with HIV. The New England Journal of Medicine, 357(23), 2359–2370. https://doi.org/10.1056/NEJMoa072375
2. Falutz J, Mamputu, J. C., Potvin, D., Moyle, G., Soulban, G., Loughrey, H., Marsolais, C., Turner, R., & Grinspoon, S. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: A pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. The Journal of Clinical Endocrinology & Metabolism, 95(9), 4291–4304. https://doi.org/10.1210/jc.2010-0490
3. Stanley TL, Feldpausch, M. N., Oh, J., et al. (2014). Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: A randomized clinical trial. JAMA, 312(4), 380–389. https://doi.org/10.1001/jama.2014.8334
4. Stanley TL, Fourman, L. T., Feldpausch, M. N., et al. (2019). Effect of tesamorelin on nonalcoholic fatty liver disease in HIV-positive individuals: A randomized, double-blind, multicenter study. The Lancet HIV, 6(12), e821–e830. https://doi.org/10.1016/S2352-3018(19)30338-8
5. Adrian S, Scherzinger, A., Sanyal, A., et al. (2019). Growth hormone-releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. The Journal of Frailty & Aging, 8(3), 154–159. https://doi.org/10.14283/jfa.2018.45
6. Mangili A, Falutz, J., Mamputu, J. C., Stepanians, M., & Hayward, B. (2015). Predictors of treatment response to tesamorelin, a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat. PLoS ONE, 10(10), e0140358. https://doi.org/10.1371/journal.pone.0140358
7. Falutz J, Allas, S., Mamputu, J. C., et al. (2008). Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS, 22(14), 1719–1728. https://doi.org/10.1097/QAD.0b013e32830a5058